NZ701419A - Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent - Google Patents
Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agentInfo
- Publication number
- NZ701419A NZ701419A NZ701419A NZ70141913A NZ701419A NZ 701419 A NZ701419 A NZ 701419A NZ 701419 A NZ701419 A NZ 701419A NZ 70141913 A NZ70141913 A NZ 70141913A NZ 701419 A NZ701419 A NZ 701419A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- chemically modified
- postpartum haemorrhage
- heparan sulphate
- modified heparin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644036P | 2012-05-08 | 2012-05-08 | |
| US201261668150P | 2012-07-05 | 2012-07-05 | |
| PCT/SE2013/050510 WO2013169194A1 (en) | 2012-05-08 | 2013-05-07 | Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ701419A true NZ701419A (en) | 2016-04-29 |
Family
ID=49551063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701419A NZ701419A (en) | 2012-05-08 | 2013-05-07 | Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150099703A1 (enExample) |
| EP (1) | EP2846810A4 (enExample) |
| JP (1) | JP2015516415A (enExample) |
| CN (1) | CN104284667A (enExample) |
| AU (1) | AU2013260209A1 (enExample) |
| BR (1) | BR112014027712B1 (enExample) |
| CA (1) | CA2868403A1 (enExample) |
| HK (1) | HK1203377A1 (enExample) |
| IL (1) | IL234752A0 (enExample) |
| MX (1) | MX2014013449A (enExample) |
| MY (1) | MY192330A (enExample) |
| NZ (1) | NZ701419A (enExample) |
| RU (1) | RU2014149230A (enExample) |
| SG (1) | SG11201407346WA (enExample) |
| UA (1) | UA117912C2 (enExample) |
| WO (1) | WO2013169194A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12502403B2 (en) | 2020-02-17 | 2025-12-23 | Dilafor Ab | Tafoxiparin for the treatment of preeclampsia |
| CA3255831A1 (en) | 2022-05-03 | 2023-11-09 | Dilafor Ab | NEW MEDICAL USE OF TAFOXIPARIN |
| EP4272749A1 (en) | 2022-05-03 | 2023-11-08 | Dilafor AB | New medical use of tafoxiparin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993810A (en) * | 1996-03-15 | 1999-11-30 | Lebovitz; Shamir Israel | Method of softening or ripening the cervix of a female mammal using collagenase |
| SE521676C2 (sv) * | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| US8071569B2 (en) * | 2002-09-20 | 2011-12-06 | Mousa Shaker A | Oxidized heparin fractions and their use in inhibiting angiogenesis |
| UA21707U (en) * | 2006-12-18 | 2007-03-15 | Valerii Ivanovych Linnikov | Method for preventing and treating thrombophilia in course of gestation and postpartum |
| US8445436B2 (en) * | 2007-12-03 | 2013-05-21 | Florida State University Research Foundation, Inc. | Oxytocin and melatonin compositions and associated methods for inducing labor |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| DK2794665T3 (da) * | 2011-12-19 | 2018-01-29 | Dilafor Ab | Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf |
| CN104203256B (zh) * | 2012-03-26 | 2017-11-24 | 迪乐方有限责任公司 | 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗 |
| NZ631279A (en) * | 2012-03-26 | 2016-06-24 | Dilafor Ab | Method for treatment of labor arrest |
-
2013
- 2013-05-07 US US14/399,450 patent/US20150099703A1/en not_active Abandoned
- 2013-05-07 AU AU2013260209A patent/AU2013260209A1/en not_active Abandoned
- 2013-05-07 CA CA2868403A patent/CA2868403A1/en not_active Abandoned
- 2013-05-07 NZ NZ701419A patent/NZ701419A/en unknown
- 2013-05-07 RU RU2014149230A patent/RU2014149230A/ru not_active Application Discontinuation
- 2013-05-07 MX MX2014013449A patent/MX2014013449A/es unknown
- 2013-05-07 HK HK15103952.3A patent/HK1203377A1/xx unknown
- 2013-05-07 UA UAA201413096A patent/UA117912C2/uk unknown
- 2013-05-07 MY MYPI2014003127A patent/MY192330A/en unknown
- 2013-05-07 SG SG11201407346WA patent/SG11201407346WA/en unknown
- 2013-05-07 CN CN201380023470.3A patent/CN104284667A/zh active Pending
- 2013-05-07 EP EP13788384.9A patent/EP2846810A4/en not_active Withdrawn
- 2013-05-07 JP JP2015511415A patent/JP2015516415A/ja active Pending
- 2013-05-07 BR BR112014027712-5A patent/BR112014027712B1/pt active IP Right Grant
- 2013-05-07 WO PCT/SE2013/050510 patent/WO2013169194A1/en not_active Ceased
-
2014
- 2014-09-21 IL IL234752A patent/IL234752A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014149230A (ru) | 2016-06-27 |
| AU2013260209A1 (en) | 2014-11-20 |
| MX2014013449A (es) | 2014-12-08 |
| CN104284667A (zh) | 2015-01-14 |
| JP2015516415A (ja) | 2015-06-11 |
| CA2868403A1 (en) | 2013-11-14 |
| WO2013169194A1 (en) | 2013-11-14 |
| UA117912C2 (uk) | 2018-10-25 |
| US20150099703A1 (en) | 2015-04-09 |
| SG11201407346WA (en) | 2014-12-30 |
| HK1203377A1 (en) | 2015-10-30 |
| EP2846810A1 (en) | 2015-03-18 |
| IL234752A0 (en) | 2014-11-30 |
| MY192330A (en) | 2022-08-17 |
| BR112014027712A2 (pt) | 2017-06-27 |
| BR112014027712B1 (pt) | 2023-12-19 |
| EP2846810A4 (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000236A1 (en) | Use of chemically modified heparin derivates in sickle cell disease | |
| MX351104B (es) | Nuevos glucosaminoglucanos con baja actividad anticoagulante. | |
| AR096438A1 (es) | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso | |
| MY210233A (en) | Methods and compositions for topical delivery | |
| EA201390600A1 (ru) | Терапевтические наночастицы с сополимерами с большим молекулярным весом | |
| MX2015007410A (es) | Membrana de hidrogel para prevencion de la adhesion. | |
| TN2010000086A1 (en) | Antiviral composition comprising a sulfated polysaccharide | |
| EA201300898A1 (ru) | Композиция для окислительного фотоактивируемого омоложения кожи, содержащая гиалуроновую кислоту, глюкозамин или аллантоин | |
| JP2011522879A5 (enExample) | ||
| NZ624749A (en) | A sulfated polysaccharide compound and the preparation and use thereof | |
| JP2015514705A5 (enExample) | ||
| RU2014143008A (ru) | Способ лечения остановки родов | |
| RU2014143017A (ru) | Препараты для индукции родов | |
| MX2014013449A (es) | Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico. | |
| HRP20230820T1 (hr) | Heparan-sulfat, s visokom stopom 3-o-sulfatiranja u glukozaminskim ostacima | |
| AR083770A1 (es) | Metodos y composiciones, kit | |
| CA2472093A1 (en) | Use of sulfated glycosaminoglycans for establishing effective labor in women | |
| WO2014127232A3 (en) | Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy | |
| JP2015516415A5 (enExample) | ||
| JP2007126453A5 (enExample) | ||
| TH152504A (th) | การบำบัดรักษาของภาวะตกเลือดหลังคลอดด้วยเฮปาริน หรือ เฮปารินซัลเฟตที่ถูกดัดแปลงทางเคมี และยากระตุ้นการหดตัวของมดลูก | |
| MX2012006966A (es) | Tratamiento de padecimientos mediados por citocina. | |
| AR086349A1 (es) | Semuloparina para la prevencion de tromboembolismo venoso en pacientes con cancer que estan recibiendo quimioterapia | |
| AR081654A1 (es) | Semuloparina para la prevencion prolongada de un suceso de mortalidad y/o morbilidad en un paciente que ha sufrido cirugia de fractura de cadera | |
| AR107011A1 (es) | Composición para el cuidado del cabello |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2018 BY CPA GLOBAL (PATRAFEE) Effective date: 20170428 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2019 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20180417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2020 BY CPA GLOBAL(PATRAFEE) AB Effective date: 20190424 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2021 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20200422 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2022 BY CAMILLA WELLIN / CPA GLOBAL Effective date: 20210409 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE Effective date: 20220407 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2024 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20230419 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2025 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20240412 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2026 BY CPA GLOBAL (PATRAFEE) AB Effective date: 20250422 |